To gain insights into the mode of action of DHODH‐targeting drugs we focused initially on an aggressive chemo‐refractory syngeneic murine AML model driven by doxycycline‐inducible expression of MLL‐AF9 and constitutive expression of oncogenic NrasG12D (hereafter referred to as MN) (Fig EV1A) (Zuber et al, 2009, 2011). The gene discussed is KMT2A; the disease is acute myeloid leukemia.